News Releases

Date Title and Summary View
Feb 08, 2021
Feb 08, 2021
Feb 05, 2021
Feb 04, 2021
Feb 03, 2021
Feb 02, 2021
Feb 02, 2021
Feb 01, 2021
Jan 29, 2021
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination 85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28 Protection
Jan 27, 2021
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.